Work over several decades has laid solid foundations for the advancement of liver cell
therapy. To date liver cell therapy in people has taken the form of hepatocyte transplantation …

The poor predictability of human liver toxicity is still causing high attrition rates of drug
candidates in the pharmaceutical industry at the non-clinical, clinical, and post-marketing …

We report the first investigation into the bioprinting of human induced pluripotent stem cells
(hiPSCs), their response to a valve-based printing process as well as their post-printing …

Background & Aims Hepatocyte-like cells (HLCs), differentiated from pluripotent stem cells
by the use of soluble factors, can model human liver function and toxicity. However, at …

There exists a worldwide shortage of donor livers available for orthotropic liver
transplantation and hepatocyte transplantation therapies. In addition to their therapeutic …

The behavior of stem cells, when they work collectively, can be much more sophisticated
than one might expect from their individual programming. This Perspective covers recent …

How are closely related lineages, including liver, pancreas, and intestines, diversified from a
common endodermal origin? Here, we apply principles learned from developmental biology …

End‐stage liver diseases are an increasing health burden, and liver transplantations are
currently the only curative treatment option. Due to a lack of donor livers, alternative …

Hepatocytes generated from human induced pluripotent stem cells (hiPSCs) are
unprecedented resources for pharmaceuticals and cell therapy. However, the in vitro …

Advanced liver disease presents a significant worldwide health and economic burden and
accounts for 3.5% of global mortality. When liver disease progresses to organ failure the …